CORE-009: ANALYTICAL CYTOMETRY SHARED RESOURCE (ACSR) PROJECT SUMMARY / ABSTRACT The Analytical Cytometry Shared Resource (ACSR) provides flow cytometry services for cancer research studies ranging from basic science to clinical trials, and especially for those needing rapid and accurate analysis of biological particles and cells. The ACSR provides OSUCCC members with the ability to obtain viable, sterile and pure populations of cells (>98%) so that they may be individually cloned, assessed for immunological function, and/or examined for specific biochemical properties with minimal manipulations. The ACSR has the following Specific Aims: 1) to provide state-of-the-art equipment and support for high-quality cancer research for OSUCCC members on a fee-for-service basis and to assist investigators with experimental design and assay development; 2) to continuously work with the OSUCCC members to provide substantial technical expertise and training for the use of state-of the-art cytometry instruments so that researchers can have 24 hour access to instruments; and, 3) to introduce OSUCCC members to new instrumentation, technology and methodologies that are being developed at the ACSR through a variety of educational outreach activities. The ACSR is located on the tenth floor of the Biomedical Research Tower (BRT); the BRT and adjacent buildings are home to most OSUCCC investigators. The ACSR is heavily used. Over the past year 5 year period, the ACSR has provided services to 146 OSUCCC members. This past year alone, the ACSR was used by 83 OSUCCC members representing all five OSUCCC scientific programs, and over the last five years it has supported over 55 NCI grants including 2 K awards, 5 P01s, 2 P50s, 1 R00, 34 R01s, 2 R03s, 6 R21s, and 3 U01s. ACSR also supports clinical trials from all five OSUCCC scientific programs. The ACSR has contributed to over 242 cancer related publications over the last grant period, including 27 with an impact factor > 10. During the next grant period, the ACSR is projected to have sufficient capacity to address a growth in OSUCCC members. Part of the ACSR future direction will be to acquire an ImageStream flow cytometer with high resolution microscopy, a BD FACSCanto II flow cytometer and a CyTOF2 Mass Cytometer, and train ACSR personnel and OSUCCC members in their usage. The ACSR leverages extensive institutional support and seeks 28.8% support from CCSG funds. The Analytical Cytometry Core is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-41
Application #
9221254
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications